CEL-SCI (CVM) Competitors

CEL-SCI (NYSE:CVM) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Does the MarketBeat Community favor CVM or TCRX?

TScan Therapeutics received 40 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 83.33% of users gave TScan Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.

Company	Underperform	Outperform
CEL-SCI	Outperform Votes No Votes	Underperform Votes 21 100.00%
TScan Therapeutics	Outperform Votes 40 83.33%	Underperform Votes 8 16.67%

Does the media refer more to CVM or TCRX?

In the previous week, TScan Therapeutics had 2 more articles in the media than CEL-SCI. MarketBeat recorded 4 mentions for TScan Therapeutics and 2 mentions for CEL-SCI. TScan Therapeutics' average media sentiment score of 0.72 beat CEL-SCI's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CEL-SCI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in CVM or TCRX?

12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 16.2% of CEL-SCI shares are owned by company insiders. Comparatively, 2.8% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, CVM or TCRX?

CEL-SCI has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Is CVM or TCRX more profitable?

CEL-SCI has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,188.88%. TScan Therapeutics' return on equity of -58.72% beat CEL-SCI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CEL-SCI	N/A	-238.05%	-104.65%
TScan Therapeutics	-1,188.88%	-58.72%	-36.02%

Which has stronger earnings & valuation, CVM or TCRX?

CEL-SCI has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CEL-SCI	N/A	N/A	-$26.92M	-$0.48	-0.50
TScan Therapeutics	$2.82M	27.13	-$89.22M	-$1.15	-1.17

Do analysts recommend CVM or TCRX?

TScan Therapeutics has a consensus price target of $9.33, indicating a potential upside of 591.36%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than CEL-SCI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CEL-SCI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TScan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

TScan Therapeutics beats CEL-SCI on 12 of the 17 factors compared between the two stocks.